Program
larazotide acetate
Also written as “Larazotide Acetate”, “Larazotide” and “Larazotide acetate”.
Its studies are mostly in Celiac Disease · Fabry Disease, led by 3 companies.
Drug pageLarazotide acetate: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 9 Meters Biopharma | 80 open or running | phase 3since Jun 14, 2018 | Aug 8, 2006 | none ahead |
| BioMarin Pharmaceuticalits history only | 30 open or running | phase 1since Nov 10, 2011 | Nov 10, 2011 | none ahead |
| Interlude Biopharmaits history only | 11 open or running | phase 3since Nov 10, 2026 | Nov 10, 2026 | Aug 2028phase 3 · NCT07944625 |
Also a collaborator on its studies: Teva Pharmaceutical Industries.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of 9 Meters Biopharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2006First study: phase 2 study in Celiac DiseaseFirst studyNCT00362856 · 80 enrolled · United States
- Oct 9, 20062 phase 1 studies in Celiac DiseaseNCT00386490, NCT00386165
- Jun 25, 2007Phase 2 study in Celiac DiseaseNCT00492960 · 171 enrolled · United States, Canada
- Feb 7, 2008Phase 2 study in Celiac DiseaseNCT00620451 · 105 enrolled · United States, Canada, Spain
- Apr 27, 2009Phase 2 study in Celiac DiseaseNCT00889473 · 42 enrolled · United States, Canada
- Jul 14, 2011Phase 2 study in Celiac DiseaseNCT01396213 · 342 enrolled · United States, Canada
- Jun 14, 2018Phase 3 study in Celiac DiseaseNCT03569007 · 307 enrolled · United States
TargetBeta
“Neuronal acetylcholine receptor; alpha3/beta4 partial agonist”ChEMBL 37, by rule
Studies
All 8 9 Meters Biopharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03569007Celiac Disease · United States | 3 | Terminated | Jul 21, 2022 | 307 |
| NCT01396213Celiac Disease · United States, Canada | 2 | Completed | Aug 20, 2013 | 342 |
| NCT00889473Celiac Disease · United States, Canada | 2 | Completed | Nov 2009 | 42 |
| NCT00620451Celiac Disease · United States, Canada, Spain | 2 | Completed | Jul 2009 | 105 |
| NCT00492960Celiac Disease · United States, Canada | 2 | Completed | Oct 2008 | 171 |
| NCT00386490Celiac Disease · United States | 1 | Completed | Feb 27, 2006 | 24 |
| NCT00386165Celiac Disease · United States | 1 | Completed | Jan 26, 2006 | 21 |
| NCT00362856Celiac Disease · United States | 2 | Completed | Mar 6, 2007 | 80 |
How it is read
Names in the registry
- “larazotide acetate”, 5 entries
- “Larazotide Acetate”, 2 entries
- “Larazotide”, 1 entry
- “Larazotide acetate”, 1 entry
- “AT1001 150 mg”, 1 entry
Conditions, from the studies’ own filings
- Celiac Disease, 9 studies
- Fabry Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.